Vir Biotechnology (VIR) has issued an update.
Vir Biotechnology, Inc. has revealed exciting preliminary results from its Phase 2 SOLSTICE trial on tobevibart and elebsiran, potential treatments for chronic hepatitis delta. Investors and analysts can look forward to a detailed discussion during an upcoming June 5 investor call, which will be live-streamed, and further insights will be shared at the EASL Congress on June 8. While the data is promising, it is forward-looking and subject to the inherent risks and uncertainties of drug development.
Find detailed analytics on VIR stock on TipRanks’ Stock Analysis page.
